Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
BP2202 (iPS cell-derived BCMA CAR-NKT cell therapy)
Applicable field (uses covered by this announcement)
Phase I clinical trial for multiple myeloma
Relationship between the counterparty and the company
BrightPath Biotherapeutics Co.,Ltd.4594
Relationship with the Company
The Company submitted an IND application to the FDA.
CounterpartyU.S. Food and Drug Administration (FDA)
The U.S. government agency responsible for food and drug administration. Other information, including its location, representative, capital, and year of establishment, is Not disclosed.
Award/certification name
Orphan Drug Designation
Awarding / certifying body
U.S. Food and Drug Administration (FDA)
Impact on Business Performance
No impact on results for the fiscal year ending March 2027
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | BP2202 (iPS cell-derived BCMA CAR-NKT cell therapy) |
| Counterparty | U.S. Food and Drug Administration (FDA) |
| Counterparty overview | The U.S. government agency responsible for food and drug administration. Other information, including its location, representative, capital, and year of establishment, is Not disclosed. |
| Relationship with the Company | The Company submitted an IND application to the FDA. |
| Applicable area | Phase I clinical trial for multiple myeloma |
| Award/certification name | Orphan Drug Designation |
| Awarding / certifying body | U.S. Food and Drug Administration (FDA) |
| Impact on Business Performance | No impact on results for the fiscal year ending March 2027 |
Items this document does not state (10)
Contract ValueOffering priceContract DateLaunch dateRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historySource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The IND application was submitted to the FDA as part of the process for beginning a Phase I clinical trial of BP2202 in the United States.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.